구조모아 (StructureMoa)항암 chemical structure spider web
방문타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-5 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Tremelimumab |
Overview Company | AstraZeneca |
Overview Modality | ANTIBODY |
Overview Target | Muscle Invasive Bladder Cancer |
Overview Indication | Hepatocellular Carcinoma |
Overview Phase | PHASE_3 |
Overview Status | RECRUITING |
Overview Content status | Curated Core |
Overview Data Confidence | Data Confidence · High |
Overview Development Signal | Development Signal · Emerging |
Overview Approval status | Investigational |
Positioning Key differentiator | novel anticancer agents in non-small cell lung cancer: a pharmacovigilance analysis using the FAERS database |
Positioning Known limitation | resistance to apoptosis, and metastasis |
MoA Mechanism | targeting antigens like GPC3, AFP, and PD-L1, have been engineered to address antigen |
MoA Biomarker | biomarkers for dual immune checkpoint blockade remain insufficiently defined |
PK/PD Half-life | 16.9 h |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse |
PK/PD Experiment | PD |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse |
Toxicology Major finding | pneumonitis/radiation pneumonitis (grade 3 or 4: 4 |
Clinical Safety signal | pneumonitis/radiation pneumonitis (grade 3 or 4: 4 |
Clinical Selected reported efficacy | ORR 84.6% |
Clinical Reported ORR | 84.6% |
Clinical Result source | ClinicalTrials.gov NCT03043872 |
Clinical Program phase | PHASE_3 |
Clinical Trial activity | No active/completed counts |
Clinical Trial ref | NCT03043872 |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-5 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Tremelimumab |
Overview Company | AstraZeneca |
Overview Modality | ANTIBODY |
Overview Target | Muscle Invasive Bladder Cancer |
Overview Indication | Hepatocellular Carcinoma |
Overview Phase | PHASE_3 |
Overview Status | RECRUITING |
Overview Content status | Curated Core |
Overview Data Confidence | Data Confidence · High |
Overview Development Signal | Development Signal · Emerging |
Overview Approval status | Investigational |
Positioning Key differentiator | novel anticancer agents in non-small cell lung cancer: a pharmacovigilance analysis using the FAERS database |
Positioning Known limitation | resistance to apoptosis, and metastasis |
MoA Mechanism | targeting antigens like GPC3, AFP, and PD-L1, have been engineered to address antigen |
MoA Biomarker | biomarkers for dual immune checkpoint blockade remain insufficiently defined |
PK/PD Half-life | 16.9 h |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse |
PK/PD Experiment | PD |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse |
Toxicology Major finding | pneumonitis/radiation pneumonitis (grade 3 or 4: 4 |
Clinical Safety signal | pneumonitis/radiation pneumonitis (grade 3 or 4: 4 |
Clinical Selected reported efficacy | ORR 84.6% |
Clinical Reported ORR | 84.6% |
Clinical Result source | ClinicalTrials.gov NCT03043872 |
Clinical Program phase | PHASE_3 |
Clinical Trial activity | No active/completed counts |
Clinical Trial ref | NCT03043872 |
추천 비교
추천 비교